Dicerna to Participate in 16th Annual Citi Biopharma Conference

Rhea-AI Summary

Dicerna Pharmaceuticals (Nasdaq: DRNA) announced that Douglas M. Fambrough, Ph.D., will participate in a virtual fireside chat at the 16th Annual Citi Biopharma Conference on Sept. 9, 2021, at 7:55 a.m. ET. This event will be accessible via an audio webcast from the "Events and Presentations" page on Dicerna's website. Dicerna is focused on developing RNAi therapeutics aimed at selectively silencing disease-causing genes, with over 20 active programs in collaboration with major pharmaceutical companies tackling various diseases.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the 16^th Annual Citi Biopharma Conference on Sept. 9, 2021 at 7:55 a.m. ET.

An audio webcast of the fireside chat will be accessible from the “Events and Presentations” page in the “Investors and Media” section of the Dicerna website at www.dicerna.com. An archived replay will be available on the Company’s website following the event.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using our proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna’s GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands the functionality and application of our flagship liver-targeted GalXC technology to tissues and cell types outside the liver, and has the potential to treat diseases across multiple therapeutic areas. In addition to our own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world’s leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and our collaborative partners, we currently have more than 20 active discovery, preclinical or clinical programs focused on cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. At Dicerna, our mission is to interfere – to silence genes, to fight disease, to restore health. For more information, visit www.dicerna.com.

Cautionary Note on Forward-Looking Statements

This press release includes forward-looking statements pertaining to the Company’s planned participation at an investor conference, which may include discussion of the Company’s business and operations, including the discovery, development and commercialization of our product candidates and technologies, and the therapeutic potential thereof, the success of our collaborations with partners and any potential future collaborations. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those relating to our preclinical research and clinical programs and other risks identified under the heading “Risk Factors” included in our most recent Form 10-Q and Form 10-K filings and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.

GalXC™ and GalXC-Plus™ are trademarks of Dicerna Pharmaceuticals, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005811/en/

Media:

Amy Trevvett

+1 617-612-6253

atrevvett@dicerna.com

Investors:

Janhavi Mohite

+1 212-362-1200

ir@dicerna.com

Source: Dicerna Pharmaceuticals, Inc.

FAQ

What is the date and time of Dicerna's participation in the Citi Biopharma Conference?

Dicerna Pharmaceuticals will participate in the Citi Biopharma Conference on Sept. 9, 2021, at 7:55 a.m. ET.

Who is representing Dicerna Pharmaceuticals at the conference?

Douglas M. Fambrough, Ph.D., President and CEO, will represent Dicerna Pharmaceuticals at the conference.

How can I access the audio webcast of Dicerna's conference participation?

The audio webcast will be available on the "Events and Presentations" page of Dicerna's website.

What is the focus of Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals focuses on developing RNAi therapeutics to selectively silence disease-causing genes.

How many active programs does Dicerna have in collaboration with pharmaceutical companies?

Dicerna currently has more than 20 active discovery, preclinical, or clinical programs in collaboration with leading pharmaceutical companies.